SPOTLIGHT: Boehringer beats Bayer drug to market

Boehringer Ingelheim won European approval for its new blood thinner Pradaxa to prevent clotting in patients after orthopedic surgery. The OK lets Pradaxa beat to market its supposed future rival, Bayer's yet-to-be-approved Xarelto (rivaroxaban). Report